FIELD: pharmaceuticals.
SUBSTANCE: invention relates to IL-17A binding peptides, inhibitors of the interaction of IL-17A with IL-17RA receptor, and to bioconjugates and pharmaceutical compositions that can be used, for example, for the treatment and/or prevention of a disease such as psoriasis or dry eye disease.
EFFECT: obtaining IL-17A binding peptides.
7 cl, 10 dwg, 11 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEOANTIGENS AND THEIR USE | 2019 |
|
RU2813924C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| PEPTIDE IMMUNOGENS TARGETING INTERLEUKIN 6 (IL-6) AND COMPOSITIONS THEREOF FOR IMMUNOTHERAPY OF DISEASES AFFECTED BY IMPAIRED IL-6 REGULATION | 2019 |
|
RU2780161C1 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| VACCINE COMPOSITION FOR TREATMENT OF CANCER | 2018 |
|
RU2782261C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| MODIFIED IGG ANTIBODIES WHICH BIND TO A TRANSFORMING GROWTH FACTOR BETA-1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2728858C2 |
| GENETIC STRUCTURE FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE | 2018 |
|
RU2757932C2 |
